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A B S T R A C T
The aim of our study is to evaluate the importance of prognostic factors, both tumor-related and therapy related, and
their impact on local recurrence rate of rectal carcinoma. It is also important to evaluate impact of chemoradiotherapy
(CRT) on local recurrence rate and survival. We used the data of 514 patients with rectal carcinoma treated at Clinic of
surgery at University Hospital Centre in Osijek, during the period from 2000 to 2007. Routine follow-up was carried out
until March of 2012 or death. Median life expectancy for all patients who underwent surgery was 98 months. 47% of pa-
tients with resection without residual tumor (R0) did not develop local recurrence after median of observation of 90
months. 5-year survival rate for patients with R0 resection was 76.4%. The patients who had preoperative serum levels of
carcinoembryonic antigen (CEA) within the normal range (<5 mg/mL) had a significantly better prognosis with 5-year
survival of 75.8%, than patients with elevated levels who had 5-year survival of 46.5%. Tumor stage had great influence
on survival and was defined by UICC TNM (International Union against Cancer, Tumor Node Metastases) classifica-
tion, 7th edition. 5-year survival rate was (93.5% for stage I, 87.4% for stage II, 58.2% for stage III, 8.1% for stage IV). Pa-
tients with low grade differentiation tumors had 5-year survival rate of 73.5%, and those with high-grade had 38.2%. We
have found that preoperative CRT significantly reduces the rate of local recurrence (5.3% vs. 14.1%), but patients who
were treated with preoperative CRT did not appear to benefit significantly in terms of their long-term prognosis, because
there was no difference in overall survival between the patients who received preoperative radiochemotherapy and those
who did not receive it (66.2% vs. 67.8%). It was found that the R-classification, anatomical extent of tumor described by
the TNM classification of the UICC, tumor grade, and preoperative CEA serum level were prognostic factors that influ-
enced survival.
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Introduction
With approximately 1600 new cases in Croatia and an
estimated 80,000 new cases in EU countries per year, rec-
tal carcinoma is one of the most prevalent tumor types.
Incidence of rectal carcinoma is strongly connected with
age because ninety percent of cases are diagnosed over
the age of 50. It is known that as many as 30 to 50% of in-
dividuals older than 50 harbor one or more adenomatous
polyps. The risk of developing rectal carcinoma contin-
ues to increase with age. Incidence in Croatia is slightly
lower than in EU countries (34/100,000 with men, and
27,8/100,000 with women)1–3. Several features make the
successful management of rectal cancer clinically chal-
lenging. The absence of a serosal barrier permits early
tumor extension into the perirectal tissues. The rectum
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also lays close to vital, and sometimes unresectable, pel-
vic structures (e.g., the bladder, ureters, iliac vessels, and
the sacrum). The compact nature of the mesorectum
within the confines of the pelvis complicates the ade-
quate removal of all mesenteric nodes at risk for meta-
static disease. Due to these specific characteristics of rec-
tal cancer, surgery alone has been associated historically
with local recurrence in up to one in four patients. Local
control and survival following surgical treatment of rec-
tal cancer have been improved by the introduction of to-
tal mesorectal excision (TME)4. The rate of local recur-
rence has been proven to have an influence on the
survival rate of afflicted patients and apart from distant
metastases loco-regional recurrence is the most impor-
tant factor determining prognosis and survival. Isolated
loco-regional recurrence of rectal carcinoma have been
reported from 5% to 33% with a median of 15%4,5. In-
creasing recurrence is also associated with increased
UICC TNM stage. The most common location is ana-
stomotic, perianastomotic and in the presacral region.
Preoperative chemoradiotherapy has been shown to sig-
nificantly decrease the local recurrence rate and because
of the potential benefits associated with preoperative
therapy, interest has evolved in adopting this approach in
rectal cancer patients6.
Many randomized trials compared preoperative vs.
postoperative radiochemotherapy (German rectal cancer
trial, CAO/ARO/AIO-94 and The National Surgical Adju-
vant Breast and Bowel Project R0-3, NSABP R0-3). Stu-
dies showed that preoperative radiochemotherapy resul-
ted with fewer local recurrences, but with no significant
difference in overall survival6–8. During the data collec-
tion period there were some changes to the therapeutic
approach; the percentage of patients treated with ra-
diochemotherapy increased from 3 to 22%; the rate of
intersphinteric resection for carcinomas in the lower
third of the rectum increased from 1% to 8%9,10. These
changes in therapeutic strategy, together with the in-
crease in sphinteric-preserving operations has brought
quality of life to the forefront. Due to fact that prognostic
factors are of special interest to estimate prognosis of the
individual patient, we analyzed the known factors that
have influence on developing of the local recurrence and
survival.
Matherials and Metods
The data of 514 patients (Table 1) treated with the
following inclusion criteria were analyzed:
¿ Solitary invasive carcinoma of the rectum, 16 cm or
less from the anal verge as measured with a recto-
sigmoidoscope.
¿ No other previous or synchronous malignant tumor.
¿ Tumor resection at the Clinic of surgery in the Uni-
versity Hospital Centre in Osijek between 2000 and
2007.
Rectal carcinoma was defined as tumor 16cm or less
from the anal verge as measured with a rigid rectosigmo-
idoscope, and was classified in three groups according to
the distance from the distal margin of the tumor to the
anal verge: 12–16 cm, upper third; 7,5 to <12 cm, middle
third; <7.5 cm, lower third.
Tumor staging (clinical and histopathological exami-
nation) was recorded according to current 7th edition of
the tumor nodemetastasis (TNM) classification by UICC.
R classification was used to determine the presence of
residual tumor in specimen by pathologist and was di-
vided in three groups:
R0 – No residual tumor
R1 –Microscopic residual tumor, tumor directly at the
resection margin
R2 – Macroscopic residual tumor
Total mesorectal excision (TME), according to the
procedure described by Heald et al., and was carried out
routinely during the study interval.
Several operating methods were used (local excision,
anterior resection, abdomino-perineal excision) and the
choice was influenced by the biology, anatomical extent
of tumor and the tumor site in the rectum.
Radiochemotherapy was used for neoadjuvant or
adjuvant therapy. Neoadjuvant radiochemotherapy was
used for patients with tumor in lower third of rectum
and in stages II and III by TNM classification.
Data was collected prospectively. Preoperative find-
ings and data on treatment and patohistological exami-
nation were collected by a standardized system. All pa-
tients were followed until March of 2012 or death. Rou-
tine follow-up was carried out at 3-month intervals for
two years, and during that period patients had colonosco-
pies after every year, abdominal ultrasound every 3
months, and tumor marker CEA serum level control ev-
ery 3 months. After first two years patients had controls
every 6 months for minimally total of 5 years. If suspi-
cion of local recurrence occurred we did CT scan, or MRI
of pelvis and in some cases PET/CT. After completion of
regular follow-up, patients or their family doctors were
contacted by mail or telephone every year until death or
end of study in March of 2012. Locoregional and distant
recurrences were documented by medical imaging and
pathological examination.
Loco-regional recurrence was defined as recurrence of
the tumor in the pelvis. Patients with recurrent cancer
are a heterogeneous group. To establish LR or pelvic dis-
ease after definitive resection of rectal cancer, we have
accepted at least one of the following major criteria: (1)
Histological confirmation; (2) Palpable or evident disease
with subsequent clinical progress; (3) Clear evidence of
bone destruction; and (4) Positive positron meission to-
mography examination, and at least one of the minor cri-
teria: (1) Progressive enlargement of soft tissue mass on
repeated computed tomography (CT) or magnetic reso-
nance (MRI) examination; (2) invasion of adjacent or-
gans; (3) subsequent rise in tumor markers; and (4) typi-
cal appearance in endoscopic ultrasound, CT or MRI
imaging.
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Cancer-related death was defined as an event, i.e.
death due to recurred locoregional carcinoma and/or dis-
tant metastases. Patients who died with metachronous
rectal carcinoma or other malignant tumors were ex-
cluded.
Statistical analysis
The Kaplan-Meier method was used to calculate rates
of loco-regional recurrence, distant metastasis and sur-
vival. For comparison of the rates of loco-regional recur-
rences and survival we used the log-rank test. To identify
independent prognostic factors, we performed a Cox re-
gression analysis. For analysis of disease free survival in
patients who had a R0 (curative resection), recurrent dis-
ease or death from any cause was defined as an event. c2
test and Fisher’s exact test were used to compare fre-
quencies, and the Mann-Whitney U-test was also used. P
value of less than <0.050 was considered to be signifi-
cant. Statistical analysis was carried out using SPSS® for
Windows® version 17.0 (SPSS, Chicago, Illinois, USA).
Results
A total of 514 patients who were treated for rectal
cancer during the study period were identified. Of these
514 patients 309 underwent anterior resection, 112 un-
derwent abdomino-perineal excision, and only 16 local
excisions were done. Median follow-up for all patients
was 64 months. Median age for all patients was 63 years,
and the majority of patients were male (62.45%). On
pre-operative evaluation the majority of patients had
stage II or III disease. 7.4% of patients received preopera-
tive chemoradiotherapy, and 48.44% of patients received
postoperative chemotherapy (Table 1). Patients who un-
derwent surgery after preoperative chemoradiotherapy
and tumor resection or had adjuvant chemoradiotherapy
had a median life expectancy of 98 months. Postoperative
mortality is included. Patients who had a palliative tu-
mor resection (R1 or R2) without evidence of primary
distant metastases had a median life expectancy of 31
months. The percentage of patients who had a primary,
resectable R0 rectal carcinoma was 83.7% (Table 2). 47%
of this group of patients did not develop distant meta-
stases or local recurrence with a survival rate of 81% af-
ter a median observation period of 64 months.
Tumor-related factors and prognosis
The parameter that has the greatest influence on the
survival of patients with rectal carcinoma is residual tu-
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TABLE 1





Age(years); median, range 63, 24–89
Follow-up(months); median, range 64, 0–120
Tumor site
Upper third 94 18.3
Middle third 234 45.5
Lower third 186 36.2
Surgical therapy
Local excision 16 3.1
Anterior resection 309 60.2
Hartmann’s procedure 21 4.0
Intersphinteric resection 56 10.9






Stage y0 5 1.0
Stage I 60 11.7
Stage II 169 32.9
Stage III 198 38.5







TUMOR RELATED SURVIVAL RATES IN CURATIVELY RESECTED








All 408 80.3 77.4–83.3
Upper third 73 76.4 68.6–84.1
Middle third 139 81.6 76.8–86.4 0.3718
Lower third 196 80.8 76.5–85.0 0.4302
ypT0 2 100.0
pT1 37 98.6 95.8–100 0.7789
pT2 124 92.0 88.3–95.8 0.0015
pT3 224 73.7 69.4–78.1 <0.0001
pT4 21 46.1 29.5–62.8 <0.0001
pN0 235 93.1 90.6–95.6
pN1 98 71.6 64.7–78.5 <0.0001
pN2 75 48.6 39.7–57.4 <0.0001
Low grade 327 83.8 80.8–86.8
High grade 81 56.7 46.8–66.7 <0.0001
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mor or R classification. 83.7% of patients had R0 resec-
tion, 3% of patients had R1 resection, and 13% of pa-
tients had R2 resection. Patients who had undergone a
resection without residual tumor R0, had a cancer-re-
lated 5-year survival rate of 76.4%, and only 3% of pa-
tients with grossly residual tumor R2, survived for 5
years (Table 4). Patients with R1 resection had 5-year
cancer related survival of 25.3%.
The tumor site in the rectum (lower, middle, upper
third) did not have an influence on the likelihood of
5-year survival (70.2%, 67.9%, 68.1%) for patients who
did not have distant metastases and who had undergone
R0 resection. The patients who had preoperative serum
levels of CEA within the normal range (<5 mg/mL) had a
significantly better prognosis with 5-year survival of
75.8% than patients with elevated levels with 46.5% of
survival (Table 4).
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TABLE 3
THERAPY RELATED SURVIVAL RATES IN CURATIVELY RESECTED PATIENTS WITH NO DISTANT METASTASES,
POSTOPERATIVE MORTALITY EXCLUDED
Therapy related factors N 5-Year survival (%) 95% CI(%) p
Anterior resection 296 80.6 77.1–84.1
Intersphinteric resection 31 82.0 70.5–93.5 0.9786
Abdominoperineal resection 81 79.1 72.9–85.3 0.7683
No RCT 313 81.6 78.2–84.9
Neoadjuvant RCT 38 83.8 75.4–92.3 0.4952
Adjuvant RCT 249 71.2 62.2–80.1 0.0212
Loco-regional recurrence, no 359 86.1 83.4–88.9
Loco-regional recurrence, yes 66 44.1 34.2–54.0 <0.0001
TABLE 4











All 514 68.1 64.0–72.1
Upper third 96 60.4 52.2–68.6 1.0
Middle third 183 67.9 60.0–75.8 0.0312 0.8 0.4–1.2 0.423
Lower third 235 70.2 67.1–73.3 0.3435 1.0 0.7–1.3 0.756
CEA normal 291 75.8 67.4–84.2 1.0
CEA abnormal 223 46.5 42.8–50.2 <0.0001 1.5 1.1–1.9 0.012
Local excision 16 94.2 91.1–97.3 1.4 0.4–5.2 0.637
Anterior resection 309 67.6 59.8–74.8 0.0012 1.0
Abdomino-perineal excision 112 65.9 61.1–70.7 0.5537 1.3 0.8–1.7 0.312
No RCT 227 67.8 63.2–72.4 1.0
Neoadjuvant RCT 38 66.2 63.5–68.9 0.8521 0.9 0.5–1.3 0.593
Adjuvant RCT 249 68.3 63.1–73.5 0.3618 0.8 0.4–1.2 0.152
R0 430 76.4 69.4–83.4 1.0
R1 15 25.3 18.9–31.7 <0.0001 4.1 2.1–8.4 <0.001
ctlparR2 67 2.9 0.0–6.0 0.0182 3.2 2.3–4.7 <0.001
Stage Y0 5 100.0
Stage I 60 93.5 91.0–96.1 0.5753 1.0
Stage II 169 87.4 83.5–91.3 0.0131 1.8 1.1–3.2 0.032
Stage III 198 58.2 50.8–65.6 <0.0001 5.3 3.2–9.1 <0.001
Stage IV 82 8.1 4.9–11.3 <0.0001 12.9 6.5–22.7 <0.001
Low grade 409 73.5 67.1–79.9 1.0
High grade 105 38.2 35.0–41.4 <0.0001 2.2 1.6–2.8 <0.001
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The next important prognostic parameter that has in-
fluence on the survival is anatomical extent of the tumor
due to UICC TNM classification. UICC stage I is associ-
ated with a 5-year survival rate of 93.5%; pT1 carcino-
mas have a significantly better prognosis 98.6% than pT2
carcinomas 92.0%.The prognosis is even significantly
worse when lymphogenus metastases is present. In stage
III, the cancer-related 5-year survival rates drops to
73.7%, and the involvement of more than three regional
lymph nodes (pN2) reduces survival to 48.6%, which is
significantly lower than the prognosis for pN1 involve-
ment 71.6% (Table 4).
Therapy-related factors and prognosis
No significant differences in terms of long-term sur-
vival rates have been shown among the available options
for surgical treatment of rectal carcinoma such as ante-
rior resection, abdomino-perineal resection, low inter-
sphinteric resection (80.6%; 82.0%; 79.1%; Table 2). The
choice of operation is limited and influenced surely by tu-
mor location,and the extent of the tumor at the time of
the diagnosis.
In our clinic, radiochemotherapy is used for neoadju-
vant (preoperative) chemoradiotherapy or adjuvant radi-
ation therapy. The majority of patients did not receive
preoperative CRT because it was not available at the
time. All 38 patients who were treated with neoadjuvant
radiochemotherapy (short-term RT 5 x 5 Gy + 5FU in
one week) and then delayed surgery (eight to ten weeks
after CRT) were patients with stage II or III of disease
and the tumor site was in middle or lower rectum. 5-year
local recurrence rate was 5.3% in this group. 48.44% of
patients received postoperative chemotherapy with 5-
-year local recurrence rate of 12.5%. 44.16% of patients
did not receive CRT and they had 14% of local recurrence
after 5 years. Although there was difference between lo-
cal recurrence rates of these groups of patients there was
no difference in overall survival (pre-op CRT-66.2%; post-
operative CRT-68.3%, no adjuvant therapy-67.8%; Table 4).
Discussion and Conclusion
Rectal carcinoma has been subject of many clinical
studies over the last 20 years, due to fact that this type of
tumor allows differentiation among, patient-related, tu-
mor-related and therapy related factors. As a result of
advances in surgical resection technique (TME) and mul-
timodal treatment, survival rates have improved and
locoregional recurrence rates have decreased1–4,6,9,11. This
aim of this study was to evaluate factors associated with
local recurrence outcomes and long-term survival of pa-
tients with rectal carcinoma.
Heald et al. suggested total mesorectal excision (TME)
as a surgical technique of choice in treatment of rectal
carcinoma in 1998, when they achieved a very low 10-
-year actuarial local recurrence rate of 4% in 200 consec-
utive patients undergoing curative anterior resection4.
Before the introduction of TME, surgery alone was asso-
ciated with local failure rates of up to 30–50%. In our
study TME was carried out for all patients and 5-year lo-
cal recurrence rate for patients who did not receive
either pre-operative or post-operative CRT was 14.4%.
Overall 5-year survival for this group of patients was
67.8% (Table 4).
For patients who are candidates for curative resec-
tion, important prognostic factor is tumor-related ana-
tomical extent, as described by the UICC TNM 7-th
classification1,16,19. The higher the classification stage,
the greater is the risk of developing loco-regional recur-
rence. There was only one patient with local recurrence
with stage I of disease. The incidence of local recurrence
reaches 15.15 % with stage III, and even 26% with stage
IV of disease compared to 8.2% with stage II of the dis-
ease (Table 4).
We have also showed that tumor related factor R-clas-
sification is very important factor for developing local re-
currence, and only those patients who undergo an R0 re-
section can, potentially be cured. In our study 83.7% of
patients were curatively resected R0 with 5-year survival
rate of 76.4% (Table 2).Comparison with survival rate of
25.3% for R1 resected patients, or only 2.9% 5-year sur-
vival rate is showing significance of R-classification. The
survival rate for patients with R0 resection can also be
influenced by the choice of therapy, due to use of neo-
adjuvant radiochemotherapy which can increase, for ex-
ample, survival rate for R0 resections in treatment of T4
rectal carcinomas19–22.
The most investigated biological tumor marker is
CEA, and it’s preoperative serum values can predict
prognosis for operated patients, and patients with high
serum levels of CEA preoperatively have worse prognosis
and significantly lower 5-year survival10,11,22.
The use of neoadjuvant or adjuvant chemoradiothe-
rapy and strategies to improve outcomes following rectal
resection have been explored throughout the world. Swe-
dish Rectal Cancer Trial which compared surgery alone
with surgery following short-term pelvic RT (5 x 5 Gy)
before the TME introduction showed decreasing local re-
currence rate and improvement in overall survival. The
German trial CAO/ARO/AIO as well as The National
Surgical Adjuvant Breast and Bowel Project R0-3 (NSABP
R0-3) compared preoperative use of CRT vs postopera-
tive use of CRT, and revealed that use of preoperative
CRT has many advantages like decreasing of local recur-
rence rate (11% vs. 7%), increasing disease free survival
(44% vs. 34%), and increasing overall survival rate (85%
vs. 78%)6–8.
Two other European studies also evaluated the use of
short-course preoperative RT with TME. Medical Re-
search Council CR07, and a Dutch TME trial showed
that there was significant difference in 5-year local re-
currence rates between patients undergoing TME (10.6%
CR07,and 10.9% Dutch TME trial),and patients under-
going preoperative RT (5.6% CR07, and 4.4% Dutch TME
trial)6–8,22–24.
In our study we showed that patients who were trea-
ted with neoadjuvant radiochemotherapy did not appear
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to benefit significantly in terms of their long-term prog-
nosis. 5-year survival rate was 67.8% for patients who did
not receive CRT vs. 66.2% for patients with neoadjuvant
CRT, and 68.3% for patients with adjuvant CRT (Table
4). This may be due to fact that the patients who receive
this treatment are those who have advanced local tumors
(stage II, or stage III). Receiving the neoadjuvant chemo-
therapy results in significantly better prognosis than
adjuvant radiochemotherapy concerning local recurren-
ce. 5-year local recurrence rate was 5.3% for patients who
have received neoadjuvant CRT compared with 14.16%
rate of patients who did not receive CRT.
After median of observation of 90 months we have an-
alyzed several prognostic factors that have influence on
developing of local recurrence and overall survival.
Our study showed that the pelvic recurrence rate is
tumor stage dependent, so the more advanced the stage
is, described by TNM classification, there is a higher
chance of developing local recurrence. Also, inadequate
removal of primary tumor described by residual tumor
classification or R-classification seems to be very impor-
tant tumor-related prognostic factor for developing of
LR. Patients with macroscopically residual tumor (R2)
had the worst prognosis with 5-year survival rates under
3%.
Because of the inadequate technical equipment at the
time of this study only 38 patients were treated with
neoadjuvant radiochemotherapy (short-term RT 5 x 5 Gy
+ 5FU in one week) and then delayed surgery (eight to
ten weeks after CRT) and they had benefit from receiv-
ing it with 5-year local recurrence rate of 5.3% in this
group.
Overall 5-year local recurrence rate for all patients in-
cluded in this study was 12,8% and it matches major ran-
domized trials in the last two decades which showed
locoregional failure dropping from 30–40% to less than
15%.
Cancer-related 5-year survival rate for patients who
were curatively resected was 80.3%, and overall 5-year
survival for all operated patients was 68.1%.
We have found that preoperative CRT significantly re-
duces the rate of local recurrence, but patients who were
treated with preoperative CRT did not appear to benefit
significantly in terms of their long-term prognosis.
When we considered all patients in our study multi-
variate analysis showed that prognostic factors with
greatest influence on local recurrence development were
R-classification, tumor stage defined by TNM classifica-
tion, preoperative serum CEA levels and use of neoadju-
vant chemoradiotherapy.
There have been many improvements in surgery and
the application of combined approaches in the manage-
ment of rectal cancer in terms of reducing of local recur-
rence, and increasing of conservative surgery rates, as
well as overall survival. Surgeons and pathologists have
been extensively investigating anatomical and technical
basis of tumor recurrence within the pelvis, and proved
that the mainstay of treatment aimed at achieving loco-
regional control is still surgery, with of course multidisci-
plinary approach.
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^IMBENICI RIZIKA ZA NASTANAK LOKALNOG RECIDIVA I PRE@IVLJENJE NAKON
OPERATIVNOG LIJE^ENJA KARCINOMA REKTUMA: REZULTATI JEDNE USTANOVE
S A @ E T A K
Cilj na{e studije je ocjena va`nosti pojedinih ~imbenika rizika, kako vezanih uz tumor, tako i onih vezanih uz tera-
piju, te njihova uloga u u nastajanju lokalnog recidiva karcinoma rektuma. Tako|er je bitno u studiji evaluirati u~inak
kemoradioterapije na nastanak lokalnog recidiva kao i na pre`ivljenje. Kori{teni su podaci 514 operiranih bolesnika sa
karcinomom rektuma, u periodu izme|u 2000. i 2007. godine, na Klinici za kirurgiju, KBC Osijek. Rutinske kontrole i
postoperativno pra}enje bolesnika su u~injeni do o`ujka 2012. godine ili do eventualne smrti bolesnika. Srednja o~eki-
vana postoperativna dob svih operiranih bolesnika bila je 98 mjeseci. 47% bolesnika sa u~injenom R0 resekcijom (resek-
cijom bez ostatnog tumora), nije razvilo lokalni recidiv nakon nakon srednje du`ine postoperativnog pra}enja od 90
mjeseci. 5-to godi{nje pre`ivljenje bolesnika kod kojih je u~injena R0 resekcija bilo je 76,4%. Bolesnici koji su imali
preoperativnu serumsku razinu karcinoembrionskog antigena (CEA) unutar normalnog referentnog raspona (<5
mg/mL) imali su statisti~ki zna~ajno bolje 5-to godi{nje pre`ivljenje (75,8%), nego bolesnici sa preoperativno povi{enom
razinom CEA (46,5%). Tumorski stadij je imao velik utjecaj na pre`ivljenje, a definiran je sa UICC TNM (International
Union Against Cancer, Tumor Node Metastases) klasifikacijom, 7. izdanjem. 5-to godi{nje pre`ivljenje bilo je (93,5% za
stadij I; 87,4% za stadij II; 58,2% za stadij III i 8,1% za stadij IV). 7,3% od ukupnog broja bolesnika koji su primili
neoadjuvantnu kemoradioterapiju imali su zna~ajno ni`i postotak lokalnog recidiva nakon 5 godina (5,3%), nego boles-
nici koji neoadjuvantnu CRT nisu primili (14,1%). Iako je neoadjuvantna terapija imala utjecaja na nastajanje lokalnog
recidiva, nije imala zna~ajan utjecaj na ukupno 5-to godi{nje pre`ivljenje (66,2% vs. 67,8%). Bolesnici sa slabo diferen-
ciranim tumorom imali su zna~ajno lo{ije 5-to godi{nje pre`ivljenje nego bolesnici sa dobro diferenciranim tumorom
(38.2% vs. 73.5%). Ova studija je pokazala da su R-klasiifikacija, stadij tumora prema TNM klasifikaciji, stupanj dife-
rencijacije tumora, povi{ena serumska razina CEA prognosti~ki ~imbenici koji utje~u na pre`ivljenje, a upotreba neo-
adjuvantne kemoradioterapije smanjuje nastanak lokalnog recidiva, no ne utje~e na ukupno 5-to godi{nje pre`ivljenje.
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